Final overall survival data from a randomized, open-label, phase II study of relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel among patients with recurrent platinum-resistant ovarian cancer Meeting Abstract
| Authors: | Colombo, N.; Van Gorp, T.; Matulonis, U.; Oaknin, A.; Grisham, R.; Provencher, D.; Fleming, G.; Olawaiye, A.; Pashova, H.; Tudor, I. C.; Dreiling, L.; Lorusso, D. |
| Abstract Title: | Final overall survival data from a randomized, open-label, phase II study of relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel among patients with recurrent platinum-resistant ovarian cancer |
| Meeting Title: | Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer |
| Journal Title: | Gynecologic Oncology |
| Volume: | 190 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Mar 15-18 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0090-8258 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2024-11-01 |
| Start Page: | S74 |
| Language: | English |
| ACCESSION: | WOS:001330731400099 |
| PROVIDER: | wos |
| DOI: | 10.1016/j.ygyno.2024.07.109 |
| Notes: | Meeting Abstract: 110 -- Source: Wos |
